Filing Analysis
Palatin Technologies, Inc. (PTN) filed an 8-K on May 18, 2026, disclosing a voluntary transfer of its common stock listing from NYSE American to the Nasdaq Capital Market. The company's Board of Directors authorized the move, with trading on NYSE expected to cease at market close on May 28, 2026, and Nasdaq trading commencing May 29, 2026. The ticker symbol "PTN" will be retained under the new exchange.
🚩 Red Flags
- Exchange downgrade from NYSE American to Nasdaq Capital Market — both are lower-tier markets, which may signal the company is migrating to maintain listing eligibility rather than for strategic reasons
- Multiple 8-K items filed simultaneously (Items 3.01, 7.01, and 9.01), which is a red flag escalator per classification guidelines
- Item 3.01 ('Notice of Delisting or Failure to Satisfy a Continued Listing Rule') is the triggering item, even though the transfer is described as voluntary — the use of this specific item number warrants scrutiny
- No explicit reason given for the exchange transfer, leaving open the possibility of underlying NYSE compliance issues
📋 Key Facts
- Filing date: May 18, 2026
- Company voluntarily withdrawing listing from NYSE American LLC
- Transfer destination: Nasdaq Capital Market (already approved by Nasdaq)
- NYSE trading expected to cease at close of trading on May 28, 2026
- Nasdaq trading expected to begin on May 29, 2026
- Ticker symbol 'PTN' will remain unchanged
- Common stock par value: $0.01 per share
- Action authorized by the Board of Directors
- Press release issued same day (May 18, 2026) as Exhibit 99.1
- Signed by Stephen T. Wills, EVP, CFO and COO
This is an amended 8-K filing (Form 8-K/A) regarding the results of Palatin Technologies' 2025 annual meeting. The company is specifically disclosing that stockholders approved a recommendation to hold non-binding advisory votes on executive compensation on an annual basis.
📋 Key Facts
- The filing amends a previous 8-K filed on July 29, 2025.
- Stockholders voted at the 2025 Annual Meeting held on July 25, 2025.
- Stockholders approved an advisory, non-binding vote to hold future stockholder advisory votes on executive compensation every year.
- The Board of Directors will include this advisory vote in proxy materials annually moving forward.
Palatin Technologies, Inc. announced the closing of an over-allotment option related to its recent firm commitment public offering. This resulted in additional gross proceeds of approximately $2.37 million and increased total offering proceeds to roughly $18.2 million.
🚩 Red Flags
- Significant dilution risk due to a large number of warrants (Series J and Series K) issued alongside common stock.
📋 Key Facts
- Underwriters (A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd.) exercised over-allotment options on November 12, 2025.
- The exercise included 280,615 shares of common stock at $6.50 per share.
- Included in the over-allotment were pre-funded warrants for 84,000 shares and Series J/K warrants totaling up to 729,230 potential shares.
- Additional gross proceeds from this exercise: ~$2.37 million.
- Total gross proceeds from the full offering (including over-allotment): ~$18.2 million.
Palatin Technologies is launching a $15.8 million public offering of common stock and warrants to regain NYSE American listing compliance and bolster equity. The company expects to resume trading on the NYSE American under ticker 'PTN' on November 12, 2025.
🚩 Red Flags
- History of delisting: Trading was suspended on May 7, 2025, due to low stock price.
- Recent Reverse Stock Split: A 1-for-50 reverse split was executed on August 11, 2025, to meet listing requirements.
- Heavy reliance on equity financing and collaboration revenue (Boehringer Ingelheim) to maintain minimum $6.0M stockholders' equity requirement.
📋 Key Facts
- Public offering of 2,430,769 shares of common stock (or pre-funded warrants) plus Series J and K warrants.
- Combined public offering price is $6.50 per share.
- Gross proceeds expected to be approximately $15.8 million; net proceeds estimated at $14.7 million.
- Series J Warrants: Exercise price $6.50, expire 18 months or upon FDA acceptance of obesity treatment IND.
- Series K Warrants: Exercise price $8.125, expire in 5 years (subject to Series J expiration terms).
- Expected closing date for the offering and resumption of NYSE American trading is November 12, 2025.
Palatin Technologies announced the achievement of a research milestone in its collaboration with Boehringer Ingelheim, triggering a €5.5 million ($6.5 million) payment. The company is also currently trading on the OTCQB following a delisting from NYSE American due to low stock price.
🚩 Red Flags
- Delisting notice: The company was delisted from NYSE American due to low stock price (trading suspended May 7, 2025).
- Currently trading on OTCQB under symbol 'PTNT' rather than a major exchange.
📋 Key Facts
- Achievement of a research milestone under Boehringer Ingelheim collaboration triggers a €5.5 million ($6.5 million) payment.
- Palatin previously received an upfront payment of €2.0 million ($2.3 million USD).
- Company is eligible for up to €18.0 million ($21.2 million USD) in near-term research milestones.
- Potential for up to €260 million ($307 million USD) in success-based development, regulatory, and commercial milestone payments.
- The agreement includes tiered royalties on net sales resulting from the collaboration.
Palatin Technologies (PTN) has completed a 1-for-50 reverse stock split to address delisting issues and has resumed trading on the OTCQB market under symbol 'PTNT'. The company was previously suspended from NYSE American due to low share price.
🚩 Red Flags
- Reverse stock split (1-for-50) is a major red flag often used to artificially inflate share price.
- Delisting from a major exchange (NYSE American) due to low stock price.
- History of trading on OTC markets (OTCQB) following delisting.
📋 Key Facts
- Completed a 1-for-50 reverse stock split of outstanding shares.
- Trading resumed on the OTCQB Market under symbol 'PTNT' effective September 10, 2025.
- Previously traded as 'PTNTD' (the 'D' typically indicating a name change or specific status during/after a split) since August 12, 2025.
- NYSE American delisted the company due to non-compliance with minimum bid price requirements under Section 1003(f)(v).
- Trading on NYSE American was suspended on May 7, 2025.
Palatin Technologies has entered into a significant Research Collaboration and License Agreement with Boehringer Ingelheim (BI) for melanocortin receptor-targeted peptides. While the deal includes substantial potential milestone payments totaling over $300M, the company is currently delisted from NYSE American and trading on the OTCQB.
🚩 Red Flags
- Delisting notice: Company was delisted from NYSE American due to low stock price; trading moved to OTCQB (symbol PTNTD).
- Trading suspension history: Trading was suspended on May 7, 2025.
- High dependency on milestone payments which are contingent on clinical/regulatory success.
📋 Key Facts
- Entered into Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim (BI) on August 14, 2025.
- Upfront payment of €2.0 million ($2.3 million USD).
- Potential near-term research milestone payments up to €18.0 million ($20.9 million USD).
- Potential success-based development, regulatory, and commercial milestone payments up to €260 million ($301.6 million USD).
- Agreement includes tiered royalties on net commercial sales of Products.
- Palatin assigned certain patent rights to BI as part of the deal.
Palatin Technologies, Inc. is amending its previous 8-K to update the timing of a 1-for-50 reverse stock split. The split is now expected to be effective after market close on August 11, 2025, with trading resuming on the OTCQB on an adjusted basis on August 12, 2025.
🚩 Red Flags
- Reverse stock split (1-for-50) typically used to combat extremely low share prices.
- History of delisting: Trading suspended on NYSE American on May 7, 2025, due to non-compliance with listing standards regarding share price.
- Current trading status is limited to the OTCQB market (Pink/OTC markets).
- The necessity of a reverse split often indicates significant downward pressure on the stock price.
📋 Key Facts
- The company is executing a 1-for-50 reverse stock split.
- Effective date expected after market close on August 11, 2025.
- Trading on the OTCQB Market (symbol: PTNT) to resume on an adjusted basis at market open on August 12, 2025.
- The delay in timing is due to pending approval from FINRA.
- The company was previously delisted from NYSE American due to low stock price.
Palatin Technologies, Inc. is executing a 1-for-50 reverse stock split effective August 8, 2025, following its delisting from the NYSE American due to low share price. The company's common stock will continue trading on the OTCQB market under the symbol PTNTD for a transition period.
🚩 Red Flags
- Reverse stock split (typically a sign of extreme distress or attempt to avoid delisting/maintain minimum bid requirements).
- Prior delisting from NYSE American due to low share price.
- Trading on OTCQB markets indicates significantly reduced liquidity and visibility compared to major exchanges.
📋 Key Facts
- 1-for-50 reverse stock split effective August 8, 2025, at 5:00 p.m. ET.
- Company was delisted from NYSE American on May 7, 2025, due to low selling price (Section 1003(f)(v) of NYSE American Company Guide).
- The split will result in every 50 shares being combined into one share.
- No fractional shares will be issued; stockholders will receive cash-in-lieu based on the 5-day average closing price preceding the effective date.
- Trading on OTCQB under symbol 'PTNTD' for 20 trading days starting August 11, 2025.
Palatin Technologies, Inc. held its annual meeting of stockholders where shareholders approved a significant reverse stock split with a ratio between 1-for-50 and 1-for-100. The company is currently trading on the OTCQB market following delisting from the NYSE American due to low share price.
🚩 Red Flags
- Reverse stock split approved (often used to combat delisting/low price)
- Delisted from NYSE American due to low share price
- Trading on OTCQB market rather than a major exchange
- Significant dilution potential via the approval of multiple series of warrants (Series B, D, and I)
📋 Key Facts
- Shareholders ratified an amendment to effect a reverse stock split at a ratio of no less than 1-for-50 and no greater than 1-for-100.
- The company was delisted from NYSE American on May 7, 2025, due to low selling price (Section 1003(f)(v)).
- Common stock is currently trading on the OTCQB market under symbol 'PTNT'.
- Stockholders approved the issuance of shares upon exercise of Series B, D, and I purchase warrants.
- The 2011 Stock Incentive Plan was amended to increase available equity awards by 3,000,000 shares.
- KPMG LLP was re-appointed as the independent registered public accounting firm for FY ending June 30, 2025.
Palatin Technologies has received a unanimous decision from the NYSE American Listing Qualifications Panel to affirm delisting proceedings due to low stock price. The company is currently trading on the OTCQB market under the symbol 'PTNT' and is appealing the decision.
🚩 Red Flags
- Delisting notice (confirmed)
- Stock already relegated to OTCQB market
- Unanimous Panel decision against the company
- Low selling price deficiency
📋 Key Facts
- NYSE American determined the company is no longer suitable for listing per Section 1003(f)(v) of the NYSE American Company Guide due to low stock price.
- Trading on NYSE American was suspended on May 7, 2025.
- The stock moved from Pink Market (PTNT) to OTCQB market (PTNT) on June 9, 2025.
- A Listing Qualifications Panel held a hearing on June 18, 2025, and unanimously affirmed the delisting decision.
- The company intends to request a review by the full Committee for Review.
- An appeal hearing is expected in late August or September 2025.
Palatin Technologies has been delisted from the NYSE American due to a low stock price and is currently trading on the OTCQB. To raise working capital, the company entered into a highly dilutive private placement of Series D Convertible Preferred Stock and warrants with its own executives and directors.
🚩 Red Flags
- Delisting from NYSE American due to low share price.
- Extreme dilution: The potential conversion and warrant exercise represent a massive increase in total shares outstanding relative to the $340k raised.
- Related-party transaction: The entire offering was taken by company insiders (CEO, CFO, and Directors).
- Death spiral features: Convertible preferred stock with an 8% cumulative dividend and low conversion price ($0.11) in a delisted micro-cap context.
📋 Key Facts
- NYSE American delisted the company; trading suspended May 7, 2025; currently trading on OTCQB under symbol 'PTNT'.
- Private placement closed June 13, 2025, raising $340,000 in gross proceeds.
- Issued 3,400 shares of Series D Convertible Preferred Stock convertible into up to 3,090,909 common shares at $0.11/share.
- Issued warrants for 6,181,818 common shares with an exercise price of $0.11.
- Purchasers include the CEO (Carl Spana), CFO (Stephen Wills), and two directors (John Prendergast and Alan Dunton).
- Preferred stock carries an 8% cumulative dividend rate.
Palatin Technologies has been suspended from the NYSE American and is commencing delisting proceedings due to a low stock price. Simultaneously, the company attempted a large-scale equity offering that failed significantly, resulting in only $1.1 million in net proceeds instead of the expected $11.5 million.
🚩 Red Flags
- Delisting notice/Trading suspension
- Significant failure of a material securities offering (90% shortfall in expected proceeds)
- Failure to regain compliance with NYSE listing standards after an 18-month period
- Extreme dilution via multiple series of warrants (Series F, G, and H) at prices near or below current trading levels
- Transition from a major exchange (NYSE American) to the OTC Pink Market
📋 Key Facts
- NYSE American suspended trading on May 7, 2025, due to low stock price (Section 1003(f)(v)).
- Company moved to OTC Pink Market on May 8, 2025.
- Original equity offering aimed for $11.5 million in net proceeds via 76.6M shares at $0.15/share.
- Due to an event under Section 2.3(b)(v) of the Purchase Agreement, investors declined to close, reducing net proceeds to only $1.1 million.
- The offering included multiple tranches of warrants (Series F, G, and H) with exercise prices ranging from $0.15 to $0.40.
Palatin Technologies, Inc. received notice from NYSE American that proceedings to delist its common stock have commenced because the company failed to regain compliance with listing standards by the end of its 18-month compliance plan on April 10, 2025.
🚩 Red Flags
- Delisting notice from a major exchange (NYSE American).
- Failure to meet compliance requirements even after an 18-month grace period.
- Potential for significant liquidity risk and downward pressure on stock price if delisting proceeds or moves to OTC markets.
📋 Key Facts
- NYSE Regulation determined the company is no longer suitable for listing under Section 1009(a) of the NYSE American Company Guide.
- The company failed to demonstrate compliance with Sections 1003(a)(i), (ii), and (iii) by the expiration of its maximum 18-month compliance plan on April 10, 2025.
- The company intends to exercise its right to appeal the delisting determination.
- Common stock will continue to trade on NYSE American during the pendency of the appeal, subject to exchange discretion.
Palatin Technologies announced positive Phase 2 clinical trial results for two separate programs: an oral MC4R agonist (PL8177) for ulcerative colitis and a combination therapy of bremelanotide with tirzepatide for obesity. Both studies met their primary endpoints.
📋 Key Facts
- March 28, 2025: Announced positive topline results from Phase 2 study of oral MC4R agonist PL8177 in ulcerative colitis.
- March 31, 2025: Announced that bremelanotide co-administered with tirzepatide met the primary endpoint in a Phase 2 obesity study.
Palatin Technologies, Inc. entered into an 'at-the-market' (ATM) sales agreement with A.G.P./Alliance Global Partners to facilitate the potential sale of up to $6.0 million in common stock.
🚩 Red Flags
- Potential for immediate equity dilution through ATM offering.
- ATM offerings are often used by micro-cap companies to raise working capital, which can signal liquidity needs.
📋 Key Facts
- Entered into an At the Market Issuance Sales Agreement on February 11, 2025.
- Aggregate offering price is approximately $6.0 million.
- Sales agent: A.G.P./Alliance Global Partners.
- Commission rate for sales agent is up to 3.0% of gross proceeds.
- Shares will be sold via an existing Form S-3 registration statement (Reg. No. 333-262555).
- The company has no obligation to sell any shares and can suspend solicitation at any time.
Palatin Technologies, Inc. entered into a registered direct offering and a concurrent private placement to raise approximately $4.7 million in gross proceeds. The offering includes common stock, pre-funded warrants, and private warrants issued to an institutional investor.
🚩 Red Flags
- Significant potential dilution: The issuance of up to 4,688,000 private warrants and over 2 million pre-funded warrants represents a substantial amount of future equity dilution.
- Warrant overhang: The large number of private warrants exercisable at $1.00 may create downward pressure on the stock price upon exercise.
- Use of proceeds is for 'general working capital,' which often indicates a need to cover immediate operational burn rather than specific growth initiatives.
📋 Key Facts
- Gross proceeds from the Offering are approximately $4.7 million before fees.
- The RD Offering consists of 2,550,000 shares of common stock at $1.00 per share and up to 2,138,000 pre-funded warrants at $0.9999 per warrant.
- Private Warrants were issued for up to 4,688,000 shares with an exercise price of $1.00, exercisable after 181 days.
- Pre-funded warrants allow the investor to avoid exceeding a 9.99% ownership threshold; they are exercisable at $0.0001 per share.
- Placement agents A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. will receive a 7.00% cash fee on gross proceeds.
- The offering is expected to close on February 10, 2025.
Palatin Technologies entered into a warrant inducement agreement to encourage the exercise of existing warrants by adjusting their strike price from $1.88 and $2.12 down to $0.875. In exchange, the company will issue significant new Series C and D warrants to the exercising holder.
🚩 Red Flags
- Significant dilution: The issuance of Series C and D warrants represents substantial potential dilution for existing shareholders.
- Drastic price reduction: Reducing exercise prices from ~$2.00 to $0.875 indicates a significant drop in perceived market value or urgent need for cash.
- Warrant overhang: The creation of millions of new warrant shares creates long-term selling pressure.
- Restrictive covenants: The 45-day moratorium on issuing equity and the 6-month restriction on variable rate transactions limit management's financial flexibility.
📋 Key Facts
- The inducement letter was entered into on December 13, 2024.
- Existing warrant exercise price adjusted from $1.88 and $2.12 down to $0.875 per share.
- The holder will purchase 3,907,679 shares at the adjusted price, generating ~$3.4 million in gross proceeds.
- Company to issue Series C Warrants for 3,907,679 shares and Series D Warrants for 1,953,839 shares.
- The transaction is expected to close on December 17, 2024.
- The company is prohibited from issuing new equity or entering variable rate transactions for a specified period (up to 6 months) following the closing.
Palatin Technologies, Inc. issued an 8-K to announce its quarterly earnings results for the period ended September 30, 2024. The filing serves as a formal notice of the release of financial results and an upcoming investor webcast.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The company issued a press release (Exhibit 99.1) containing results of operations and financial condition.
- A teleconference and webcast were scheduled for November 14, 2024, at 11:00 a.m. ET to discuss corporate developments.
Palatin Technologies, Inc. received a notice from NYSE American stating it is in non-compliance with stockholders' equity requirements. The company has been granted a compliance plan period through April 10, 2025.
🚩 Red Flags
- Delisting notice/Non-compliance with exchange listing standards
- Chronic failure to meet minimum stockholders' equity requirements (multiple sections of the Company Guide)
- History of net losses in recent fiscal years contributing to equity depletion
📋 Key Facts
- Received letter from NYSE American LLC on October 4, 2024, regarding non-compliance with Section 1003(a)(iii) of the Company Guide.
- Non-compliance is due to stockholders' equity falling below the $6 million threshold required for companies with recent net losses.
- The company was already in non-compliance with Sections 1003(a)(i) and (ii) regarding lower equity thresholds ($2M and $4M respectively).
- NYSE American has accepted a compliance plan, granting the company until April 10, 2025, to regain compliance.
- The company is subject to quarterly monitoring by the Exchange during this period.
Palatin Technologies, Inc. issued a press release announcing its financial results for the fiscal year ended June 30, 2024. The filing serves as a formal notification of the earnings release and an upcoming webcast to discuss corporate developments.
📋 Key Facts
- Fiscal year end: June 30, 2024
- Report date: October 1, 2024
- The company held/is holding a teleconference and webcast on October 1, 2024, at 11:00 a.m. ET to discuss results and corporate updates.
Palatin Technologies, Inc. has announced the upcoming annual meeting of stockholders for the fiscal year ended June 30, 2024. The company provided specific dates for the meeting, record date, and deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: December 12, 2024
- Record Date: October 28, 2024
- Deadline for Rule 14a-8 shareholder proposals: October 21, 2024
- Deadline for director nominations/bylaw proposals: September 13, 2024
Palatin Technologies, Inc. held its annual meeting of stockholders on June 27, 2024. The filing reports the results of shareholder votes regarding director elections, auditor ratification, stock incentive plan amendments, and executive compensation.
🚩 Red Flags
- Low voter turnout: Only approximately 44% of total possible votes were present at the meeting (7.1M out of 16.1M).
📋 Key Facts
- Annual Meeting held on June 27, 2024.
- Seven directors were elected to serve until the next annual meeting: Carl Spana, John K.A. Prendergast, Robert K. deVeer, Jr., J. Stanley Hull, Alan W. Dunton, Arlene M. Morris, and Anthony M. Manning.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2024.
- Stockholders approved an amendment to the 2011 Stock Incentive Plan to increase available shares by 1,000,000.
- Stockholders advised approval of named executive officer compensation for the fiscal year ended June 30, 2023.
- Total votes present at meeting (in person or proxy) were 7,137,392 out of 16,141,973 total possible votes.
Palatin Technologies entered into an inducement letter with a warrant holder to facilitate the exercise of existing warrants at a reduced price. This transaction involves significant potential dilution through the issuance of millions of new shares and warrants.
🚩 Red Flags
- Significant potential dilution: The issuance of nearly 5 million new warrants and the exercise of existing ones will significantly increase the share count.
- Warrant Inducement/Downround characteristics: Lowering the exercise price to $1.88 suggests a need for immediate liquidity at unfavorable terms for existing shareholders.
- Requirement for S-3 filing: Indicates the company needs to register new shares quickly, often a sign of urgent capital needs.
📋 Key Facts
- The company expects to receive approximately $6.1 million in gross proceeds from the exercise of 3,233,277 existing warrants.
- The exercise price for these existing warrants was lowered to $1.88 per share as part of the inducement.
- In exchange, the company is issuing 4,849,915 new warrants (Series A and Series B) to the holder.
- A portion of the Series B Warrants (1,624,201 shares) is subject to stockholder approval.
- The company plans to file an S-3 registration statement on or before July 30, 2024, to register the resale of these shares.
Palatin Technologies, Inc. issued an 8-K to announce its quarterly earnings results for the period ended March 31, 2024. The filing serves as a formal notice of the release of financial results and an upcoming investor webcast.
📋 Key Facts
- Report date: May 15, 2024
- Quarterly reporting period: Quarter ended March 31, 2024
- The company issued a press release (Exhibit 99.1) containing results of operations and financial condition.
- A teleconference/webcast was scheduled for May 15, 2024, at 11:00 a.m. ET to discuss results and corporate developments.
Palatin Technologies Inc. issued an 8-K to announce its quarterly earnings results for the period ended December 31, 2023. The filing serves as a formal announcement of the release of financial results and an accompanying webcast.
📋 Key Facts
- The company reported results for the quarter ended December 31, 2023.
- A press release was issued on February 15, 2024, containing detailed financial information (Exhibit 99.1).
- Management held a teleconference and webcast on February 15, 2024, to discuss operations and corporate developments.
Palatin Technologies completed a registered direct offering and a concurrent private placement of warrants on February 1, 2024. The company raised approximately $9.2 million in net proceeds to fund general working capital.
🚩 Red Flags
- Issuance of warrants at a significant discount to the placement agent's exercise price ($6.825 vs $5.46), indicating potential dilution.
- The company is raising capital for 'general working capital,' which often suggests limited cash runway.
📋 Key Facts
- Completed a registered direct offering of 1,831,503 shares of common stock at $5.46 per share.
- Issued 1,831,503 private warrants with an exercise price of $5.46, exercisable for four years starting six months after issuance.
- Net proceeds from the offering are approximately $9.2 million after fees and expenses.
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee plus warrants to purchase 91,575 shares at an exercise price of $6.825.
- The company previously divested its Vyleesi product for an upfront payment of $9.5 million (totaling $12 million) with potential milestones up to $159 million.